Lundbeck announces FDA acceptance of NDA submission for Carbamazepine IV Captisol licensee Lundbeck LLC today announced that the U.S. Food and Drug Administration has accepted for review a New Drug Application for its investigational therapy intravenous carbamazepine, an intravenous formulation of the anti-epileptic drug carbamazepine. An action letter is anticipated before the end of 2014. Carbella Injection is the proposed U.S. trade name. With acceptance of the NDA filing, Ligand earns a $200,000 milestone payment.
News For LGND From The Last 14 Days
Check below for free stories on LGND the last two weeks.